Impact of Metabolic-Associated Fatty Liver Disease on the Severity and Structural Progression of Diabetic Retinopathy in Type 2 Diabetes Mellitus
PDF
ZENODO

Keywords

Metabolic-associated fatty liver disease, diabetic retinopathy, macular edema, optical coherence tomography, hepatokines, blood-retinal barrier, microvascular complications, systemic inflammation.

Abstract

Diabetic retinopathy represents a devastating microvascular complication traditionally conceptualized strictly as the consequence of localized retinal capillary ischemia and chronic hyperglycemic toxicity. The modern diagnostic paradigm recognizing metabolic-associated fatty liver disease (MAFLD) as a highly active systemic pathology requires a radical reevaluation of how ectopic hepatic steatosis influences distant neurovascular networks. This prospective observational investigation aimed to quantify the exact clinical and morphofunctional impact of MAFLD on the progression velocity of diabetic retinopathy. An analytical cohort comprising 315 adult patients with established Type 2 Diabetes Mellitus was stratified based on the presence or absence of concomitant MAFLD and monitored continuously over a 36-month longitudinal trajectory. Utilizing high-resolution spectral-domain optical coherence tomography and ultra-widefield fundus photography, the structural degradation of the blood-retinal barrier was meticulously mapped. The resultant data exposed a profoundly accelerated ophthalmic deterioration in the dual-pathology cohort. Patients harboring MAFLD demonstrated a 2.8-fold higher incidence of progression to vision-threatening proliferative diabetic retinopathy compared to their isolated diabetes counterparts. Central subfield macular thickness, the definitive marker of diabetic macular edema, expanded aggressively in the MAFLD arm, increasing by an average of 48.4 ± 12.1 μm annually, sharply contrasting the 14.2 ± 5.6 μm annual expansion observed in the non-steatotic group. Advanced hepatic fibrogenesis, quantitatively assessed via the non-invasive FIB-4 index, exhibited a dominant independent correlation with retinal neuroglial degradation and capillary non-perfusion areas (r = 0.69, p < 0.001). The steatotic liver operates as a powerful endocrine disruptor, continuously secreting pro-angiogenic and pro-inflammatory hepatokines that fundamentally compromise retinal pericyte survival. Integrating transient elastography and comprehensive hepatic profiling into routine ophthalmological screening algorithms provides a critical prognostic advantage, facilitating the early deployment of targeted systemic interventions before irreversible retinal architectural collapse occurs.

PDF
ZENODO

References

1. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202-209.

2. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016;65(3):589-600.

3. Song X, Qiu F, Song K, Li B. Metabolic-associated fatty liver disease and the risk of diabetic retinopathy in patients with type 2 diabetes. Front Endocrinol. 2021; 12:654955.

4. Lv X, Dong Y, Hu D, Li Y, Yang Z. Nonalcoholic fatty liver disease and microvascular complications of type 2 diabetes. World J Gastroenterol. 2020;26(46):7282-7299.

5. Zhang S, Du T, Zhang J, Lu H, Lin X, Xie J, et al. The association between non-alcoholic fatty liver disease and diabetic retinopathy: a systematic review and meta-analysis. Diabetol Metab Syndr. 2019; 11:64.

6. Targher G, Mantovani A, Pichiri I, Mingolla L, Cavalieri V, Mantovani W, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease and retinopathy in type 1 diabetes. Diabetes Care. 2014;37(6):1729-1736.

7. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366(13):1227-1239.

8. Wu Y, Ding Y, Lu C, Yin L, Chen P, Zhang Q. Hepatic steatosis is associated with proliferative diabetic retinopathy in patients with type 2 diabetes. J Diabetes Res. 2019; 2019:7251313.

9. Mantovani A, Zaza G, Byrne CD, Lonardo A, Zoppini G, Bonora E, et al. Nonalcoholic fatty liver disease increases risk of incident chronic microvascular complications: A systematic review. Metabolism. 2018; 79:64-76.

10. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124-136.

11. Brea A, Mosquera D, Martín E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with cardiovascular and microvascular complications. Arterioscler Thromb Vasc Biol. 2005;25(5):1045-1050.

12. Zheng KI, Sun DQ, Jin Y, Zhu PW, Zheng MH. Clinical utility of the MAFLD definition in determining microvascular risks. J Hepatol. 2021;74(4):989-991

13. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010;59(7):969-974.

14. Viazzi F, Piscitelli P, Giorda C, Ceriello A, Genovese S, Russo G, et al. Metabolic syndrome, serum uric acid and retinal risk in patients with T2D. PLoS One. 2017;12(4):e0176058.

15. Byrne CD, Targher G. NAFLD: a multisystem disease bridging the liver and the microvasculature. J Hepatol. 2015;62(1 Suppl):S47-S64.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.